1 recruiting. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Recruiting 1 |
Follow INCA33890: new trials by email Literature Review of INCA33890 trials Research Report on INCA33890
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer INCA33890, Placebo, Bevacizumab - CRC (Colorectal Cancer) | Phase 3 | Recruiting | Incyte Corporation | 700 | 2026-03-05 | 2026-10-30 |
Colonic Neoplasms (1) · Colorectal Neoplasms (1)
Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Canada (1) · China (1) · Denmark (1) · France (1) · Georgia (1) · Germany (1) · Italy (1) · Japan (1) · Netherlands (1) · Norway (1)
2025 (1)